BiosciNews

This week the European Medicines Agency has reviewed the current knowledge about long term safety issues with growth hormone treatment. This should give reassurance that general alteration to GH prescribing policy is not required and that treatment should be given within the product prescribing indications, adhering to recommended dosage schedules.

As you may be aware, the ESPE Clinical Practice Committee was involved in assisting with the establishment of the European SAGhE safety and efficacy study which is currently underway, but full results are not expected for at least another year.

EMA press release

European Medicines Agency update on growth hormone treatment

Share this story

Top stories

Most read